Haemonetics (Haemonetics) EBIT per Share : $3.31 (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Haemonetics EBIT per Share?

Haemonetics's EBIT per Share for the three months ended in Dec. 2023 was $0.89. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.31.

During the past 12 months, the average EBIT per Share Growth Rate of Haemonetics was 29.00% per year. During the past 3 years, the average EBIT per Share Growth Rate was 2.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 12.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Haemonetics's EBIT per Share or its related term are showing as below:

HAE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -31.8 Med: 2 Max: 54.7
Current: 2.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Haemonetics was 54.70% per year. The lowest was -31.80% per year. And the median was 2.00% per year.

HAE's 3-Year EBIT Growth Rate is ranked worse than
56.91% of 724 companies
in the Medical Devices & Instruments industry
Industry Median: 6.75 vs HAE: 2.40

Haemonetics's EBIT for the three months ended in Dec. 2023 was $46 Mil.

Haemonetics EBIT per Share Historical Data

The historical data trend for Haemonetics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics EBIT per Share Chart

Haemonetics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

1.58

2.00

1.75

1.57

3.03

Haemonetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.85	0.69	1.05	0.69	0.89

Haemonetics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Haemonetics's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	156.033	/	51.420
=	3.03

Haemonetics's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	45.978	/	51.445
=	0.89

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.31

Haemonetics (NYSE:HAE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Haemonetics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Haemonetics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (Haemonetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

HAZ:Germany

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Executives

Stewart W Strong	officer: President, Global Hospital	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni	officer: EVP, Chief Technology Officer	HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant	director	2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens	officer: EVP, Global Manufacturing	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil	officer: EVP and General Counsel	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell	officer: VP, Chief Accounting Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin	officer: President, Global Plasma & BC	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller	officer: SVP, Human Resources	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll	director	PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein	officer: VP, Corporate Controller	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon,	director, officer: President & CEO	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca	officer: EVP, Chief Financial Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr.	officer: EVP, Chief Financial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson	director	16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277